A recent prospective, multicentric, observational study conducted in patients with diabetes assessed the real-world...

The increased alpha and beta cell sensitivity to glucose by DPP4 inhibitors modulate not only chronic hyperglycemia...

Vildagliptin, a potent dipeptidyl peptidase IV inhibitor (DPP-4i), is usually administered twice daily to provide...

Among the gliptins, vildagliptin is the only therapy requiring twice-daily dosing and thus adversely impacts patient...

Vildagliptin has established itself over the years by controlling the blood sugar levels in patients with type 2...

Vildagliptin has established its efficacy over the years by displaying significant HbA1c lowering accompanied by body...

Vildagliptin, an oral hypoglycemic agent, acts by inhibiting the dipeptidyl peptidase-4 enzyme. The clinical efficacy...